The Rising Demand for CBG in Asia Pacific: Market Trends & Growth Factors

"The Asia Pacific cannabigerol (CBG) market is on a steady upward trajectory, fueled by increasing consumer awareness of cannabinoids, the expansion of legalization frameworks, and a growing demand for plant-based therapies. Countries such as Australia, Japan, South Korea, and Thailand are at the forefront of cannabinoid research and regulatory progress, creating a favorable environment for the commercialization of CBG. The potential therapeutic benefits of CBG, especially in managing pain, inflammation, neurological disorders, and cancer treatment, are attracting considerable interest from the pharmaceutical and wellness sectors, even as medical cannabis markets in the region are still evolving.

The demand for natural, non-psychoactive cannabinoids like CBG is further accelerated by the rising incidence of chronic diseases, mental health disorders, and lifestyle-related health issues. The nutraceutical, cosmeceutical, and personal care industries are also investigating CBG-infused products, recognizing its anti-inflammatory, antibacterial, and neuroprotective traits. Nonetheless, challenges such as regulatory uncertainties, high production costs, and limited consumer awareness may hinder market growth. However, ongoing investments in research and development, along with advancements in cannabinoid extraction and synthesis, are likely to improve the availability and affordability of CBG products, positioning the Asia Pacific market for significant expansion in the coming years."

The Asia Pacific Cannabigerol market was valued at USD 107 Million in 2024 and is projected to reach USD 294 Million by 2031, with a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030.

Moreover, as attitudes towards cannabis-based therapies evolve and regulations start to ease in countries like Japan, South Korea, and Australia, it has become easier for consumers to access these products. The region's large population and the booming wellness industry are also significant contributors to the rising interest in CBG in various forms, including supplements, cosmetics, and therapeutic items.

Additionally, there’s a growing preference for natural and plant-based ingredients in skincare and personal care products, which is driving the popularity of formulations infused with CBG. With ongoing research and development focused on CBG in the Asia Pacific region, it's anticipated that this market will continue to grow and become a key player in the global CBG landscape in the years to come.

The demand for CBG products is increasing in the area as people learn more about the health advantages of CBG, such as its neuroprotective and anti-inflammatory properties.

Consumers in the Asia Pacific region are becoming increasingly aware of the potential health benefits of cannabigerol (CBG). Research indicates that CBG possesses anti-inflammatory, neuroprotective, antibacterial, and anti-anxiety properties, making it a promising ingredient for health and wellness applications. As more individuals seek natural and plant-based alternatives to conventional pharmaceuticals, the demand for CBG-infused products is on the rise.

Furthermore, social media, wellness influencers, and educational initiatives by cannabis companies are helping to spread awareness about the benefits of CBG. The increasing prevalence of chronic conditions such as arthritis, neurodegenerative diseases, and anxiety disorders in the region is further fueling interest in CBG-based therapeutic solutions. This growing awareness is expected to boost consumer adoption, particularly in markets like Japan, South Korea, and Australia, where there is a strong interest in functional wellness products.

The manufacturing and distribution of goods containing CBG is being made easier by the liberalisation of cannabis laws in a number of Asia Pacific nations.

Asia Pacific's legislative landscape is steadily improving for goods derived from cannabis, such as CBG. Progressive measures have been made by nations including South Korea, Thailand, and Australia to legalise cannabis-based medications, enabling regulated cannabinoid research and commercialisation. Thailand, for instance, has taken the lead in medical cannabis reform by allowing the sale of healthcare items derived from cannabinoids and the cultivation of cannabis. The Therapeutic Goods Administration (TGA) in Australia has loosened regulations pertaining to medications containing cannabinoids, which has allowed CBG to gain more market share. The expansion of CBG products in the area may be made possible by additional regulatory reforms as more countries acknowledge the potential medical and economic advantages of cannabis.

The increasing focus on natural and plant-based health products is boosting the demand for CBG in supplements, cosmetics, and wellness solutions.

The Asia Pacific region is witnessing a significant rise in health-conscious consumers who are seeking natural remedies and functional ingredients. The wellness industry, which includes dietary supplements, herbal medicine, and organic skincare, is thriving in countries such as China, India, and Japan. CBG, often referred to as the "mother of all cannabinoids," is gaining attention as an innovative and effective wellness ingredient. Its uses in stress relief, pain management, and skincare align well with the growing demand for holistic health solutions. Furthermore, premium beauty brands and nutraceutical companies are incorporating CBG into their product lines, taking advantage of its antioxidant and anti-aging properties. This trend is expected to accelerate as consumers increasingly prioritize plant-based, non-toxic, and sustainable wellness products.

CBG's significance for health and wellness is growing as medicines produced from cannabis are increasingly accepted for use in medicine and therapy.

Cannabinoid-based products, including cannabidiol (CBD) and tetrahydrocannabinol (THC), have gained significant popularity in regions where cannabis regulations are becoming more relaxed. The increasing demand for CBD has also paved the way for cannabigerol (CBG), which is now being investigated for its additional benefits. As consumers become more familiar with cannabinoids and their potential uses, the market for non-psychoactive compounds like CBG is expanding. Many consumers are actively seeking alternatives to traditional medications, particularly for issues such as anxiety, chronic pain, and inflammation, areas where CBG has shown promising effects. In countries where CBD has already become popular, CBG is emerging as a novel and complementary cannabinoid, with potential applications in pharmaceuticals, personal care products, and functional foods.

Ongoing scientific studies and trials on CBG's medicinal benefits are leading to more product innovation and market expansion in the region.

Asia Pacific is seeing an increase in cannabis research and development (R&D) spending, which is resulting in new developments in CBG-based products. Clinical trials are being conducted by universities, biotech businesses, and pharmaceutical corporations to investigate the therapeutic potential of CBG, namely in areas like neuroprotection, anti-inflammatory therapy, and antibacterial applications. Continued research and development is essential to proving the safety and effectiveness of CBG, which will accelerate its use in wellness and medicinal applications. In an effort to improve CBG's efficacy and bioavailability, businesses are also experimenting with novel extraction and formulation methods. Consumers and regulatory agencies are become more open to the broad use of CBG as the body of scientific information demonstrating its advantages keeps increasing.

Competitive Landscape

Some of the major companies operating within the Cannabigerol market are: Mile High Labs, GenCanna, ZERO POINT EXTRACTION LLC, Willow Biosciences, Hemptown, Charlottes Web, Canatura, CBDistillery and Others.